Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent

Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent PR Newswire LONDON, July 5, 2012 - New drug formulations and strong product pipelines expected to restore growth beyond 2013 LONDON, July 5, 2012 /PRNewswire/ -- Patent expiry of key blockbuster atypical antipsychotic drugs is likely to cause a decline in growth of the European bipolar disorder therapeutics market until 2013. However, approval of new drugs and improved depot formulations are expected to present growth opportunities from 2014 to 2018. New analysis from Frost & Sullivan (http://www.pharma.frost.com), Analysis of the European Bipolar-disorder Therapeutics Market, finds that the market earned revenues of $1.20 billion in 2011 and estimates this to reach approximately $1.22 billion in 2018, at a compound annual growth rate (CAGR) of 0.2 percent. Patent expiry of several key blockbuster atypical antipsychotics, including Seroquel from AstraZeneca, the only approved atypical antipsychotic for both bipolar mania and depression, is one of the key challenges for the market participants. "As generic equivalents of these blockbuster drugs reach the market, drug prices are expected to fall between 30-60 percent, causing an overall decrease of 10.1 percent in the European bipolar disorder therapeutics market until 2013," noted Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram.